Fig. 3.
The rate of abnormal TCR BV gene families within CD4+ (a) and CD8+ T cells (b) in all of patients before and after treated by mIFL combination of bevacizumab (the first 12 bars on the X-axis) or mIFL alone (the last 6 bars on the X-axis)
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.